Floatz logo

xyf19 car-t cell

CD19 Positive

Xijing HospitalCell therapyPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the CD19 Positive cohort.

Asset / SponsorPhaseRating
Fludarabine
Jonsson Comprehensive Cancer Center
Phase 1/2B
Cyclophosphamide
Jonsson Comprehensive Cancer Center
Phase 1/2B
Autologous Cd19/Cd22 Chimeric Antigen Receptor T-Cells
M.D. Anderson Cancer Center
Phase 1/2CCC
Cytosin-Arabinosid
M.D. Anderson Cancer Center
Phase 1/2CCC
Epirubicin
City of Hope Medical Center
Phase 1/2CCC

View all 18 →

Same molecule, other indications

xyf19 car-t cell is also rated in:

acute lymphoblastic leukemiaDormant
CC
Indicative ·
43 / 100
View asset →
B-cell non-Hodgkin lymphomaDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →